Guidance

Regulatory considerations for therapeutic use of bacteriophages in the UK

This publication clarifies which regulatory guidelines should be followed, and which apply, in the development of phage therapeutic products.

Documents

Regulatory considerations for therapeutic use of bacteriophages in the UK

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The MHRA has compiled a document containing all the relevant regulatory guidance pertinent to the development of phage therapeutic products. Regulatory agencies and organisations have produced documentation to help outline the regulatory framework, but regulatory guidance is not always easy for product developers to find and/or understand; this publication brings all the pertinent regulatory information into one place. The MHRA document includes guidance for licensed and unlicensed medicines, from preclinical development to pharmacovigilance activities post-licensure.

We hope that this publication will help the community navigate the regulatory frameworks and support the development of products that will ultimately help patients.

Updates to this page

Published 4 June 2025

Sign up for emails or print this page